Sugi Predict

Sugi Predict / Compounds / SCHEMBL4040336

SCHEMBL4040336

SCHEMBL4040336

CC(=O)Nc1ccc(C)cc1CN1CCNCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.43
▸ MEN1 O00255 4/20 0.43
▸ KMT2A Q03164 4/20 0.43
▸ POLB P06746 2/20 0.43
▸ CHRM3 P20309 2/20 0.42
▸ TP53 P04637 2/20 0.41
▸ MAPT P10636 1/20 0.41
▸ MOK Q9UQ07 3/20 0.41
▸ NPC1 O15118 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ CXCR4 P61073 1/20 0.41
▸ ALOX15 P16050 1/20 0.40
▸ SOS1 Q07889 1/20 0.39
▸ HTR6 P50406 2/20 0.39
▸ HPGD P15428 1/20 0.39
▸ ABL1 P00519 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ BCR P11274 1/20 0.39
▸ MKNK1 Q9BUB5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11619286 0.86 KDM4E (0.52) MEN1KMT2APOLBTP53MAPT
SCHEMBL28986035 0.77 KDM5C (0.49) LMNACHRM3TP53NPC1RAB9A
SCHEMBL15785524 0.76 LMNA (0.50) LMNAMEN1KMT2ACHRM3MOK
SCHEMBL22425608 0.76 LMNA (0.61) LMNAPOLBSMN1; SMN2CXCR4ALOX15
SCHEMBL2925321 0.75 LMNA (0.63) LMNAMEN1KMT2APOLBCXCR4
SCHEMBL13905148 0.75 CYP1A2 (0.50) LMNAMEN1KMT2APOLBMAPT
SCHEMBL20150073 0.74 LMNA (0.45) LMNAMEN1KMT2APOLBCHRM3
SCHEMBL22547352 0.74 ALDH1A1 (0.48) LMNAMEN1KMT2APOLBTP53
SCHEMBL7768342 0.74 CHRM3 (0.48) MEN1KMT2APOLBCHRM3MOK
SCHEMBL2892719 0.74 KMT2A (0.47) MEN1KMT2APOLBMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1436291-B1 INDOLIZINES AS KINASE PROTEIN INHIBITORS AVENTIS PHARMA SA (FR) 2009-01-14 — — EP disclosed
CN-100391958-C Compound (I) AVENTIS PHARMA SA (FR) 2008-06-04 — — CN disclosed
US-20070238734-A1 JNK INHIBITORS SANOLI-AVENTIS (FR) 2007-10-11 — — US disclosed
US-7148215-B2 Prodrugs as antihistamines or anticarcinogenic agents AVENTIS PHARMA S.A. (FR) 2006-12-12 — — US disclosed
US-20050009831-A1 Pyrrolo[1,2-a]pyrazine-8-carboxamides are JNK inhibitors, useful as anticarcinogenic agents AVENTIS PHARMA S.A, (FR) 2005-01-13 — — US disclosed
CN-1556807-A Chemical compounds �㶫��������ҽҩ�ɷ����޹�˾ 2004-12-22 — — CN disclosed
EP-1436291-A2 INDOLIZINES AS KINASE PROTEIN INHIBITORS Aventis Pharma S.A. (FR) 2004-07-14 — — EP disclosed
WO-2003024967-A2 INDOLIZINES AS KINASE PROTEIN INHIBITORS AVENTIS PHARMA S.A. (FR) 2003-03-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238734-A1 JNK INHIBITORS MAP3K7, MAPKAPK2, MAPK7 LMNA 3702/4885MEN1 3865/4885KMT2A 2686/4885
US-20050009831-A1 Pyrrolo[1,2-a]pyrazine-8-carboxamides are JNK inhibitors, useful as anticarcinogenic agents CNKSR1, ROS1, NRAS LMNA 4110/4885MEN1 3716/4885KMT2A 1910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.